Lundbeck after record quarter: There is still uncertainty

Pharmaceutical group Lundbeck has had a great start to 2018, but uncertainty about the generic competition towards the end of the year still makes the company cautious in terms of expectations.

Photo: /Ritzau Scanpix/Jeppe Bøje Nielsen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles